In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?
about
Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.MMP mediated degradation of type VI collagen is highly associated with liver fibrosis--identification and validation of a novel biochemical marker assayDoes increased local bone resorption secondary to breast and prostate cancer result in increased cartilage degradation?Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon CalcitoninTibolone inhibits bone resorption without secondary positive effects on cartilage degradation.Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitoninInvestigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytesHuman macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processesBiochemical markers identify influences on bone and cartilage degradation in osteoarthritis--the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation.Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats.Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis.Acute Myocardial Infarction and Pulmonary Diseases Result in Two Different Degradation Profiles of Elastin as Quantified by Two Novel ELISAsMeasurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type iii, in a rat model of reversible carbon-tetrachloride-induced fibrosis.Characterization of an Ex vivo Femoral Head Model Assessed by Markers of Bone and Cartilage Turnover.Will posttranslational modifications of brain proteins provide novel serological markers for dementias?Seasonal variation in calcitropic hormones and bone accrual in puberty.Atherofibrosis - a unique and common process of the disease pathogenesis of atherosclerosis and fibrosis - lessons for biomarker developmentExtracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.Biochemical markers in preclinical models of osteoporosis.Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases.Fragmentation of decorin, biglycan, lumican and keratocan is elevated in degenerate human meniscus, knee and hip articular cartilages compared with age-matched macroscopically normal and control tissuesInfluence of food intake on the bioavailability and efficacy of oral calcitonin.Identification of progressors in osteoarthritis by combining biochemical and MRI-based markersBiochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.Application of biochemical markers in development of drugs for treatment of osteoarthritis.Serum biomarkers as signals for risk and severity of work-related musculoskeletal injury.Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.Post-translational modifications of the extracellular matrix are key events in cancer progression: opportunities for biochemical marker development.Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar.Biological relevance of citrullinations: diagnostic, prognostic and therapeutic options.Protein degradation fragments as diagnostic and prognostic biomarkers of connective tissue diseases: understanding the extracellular matrix message and implication for current and future serological biomarkers.Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activityCartilage formation measured by a novel PIINP assay suggests that IGF-I does not stimulate but maintains cartilage formation ex vivo.
P2860
Q27687777-2C0D4AFC-C903-4048-A4F6-61B9F6F501C5Q28477074-432D573B-C790-4D89-A95F-98F70F447ABFQ33347582-7C4DC428-E80F-4B7B-94CE-1E5EB63F0FD7Q33368276-600AE0A1-85C4-4C8C-B115-A4FE0FA2F525Q33385519-47184F39-FA9F-4154-B7E0-A9918CD17590Q33389566-B031A94E-ADAE-4D61-94AF-7D129A53521FQ33549568-DBC20A14-67CF-464E-820A-95FA647E4038Q33561251-5368B60A-6B22-47E3-A315-33403C8BAB9CQ33610773-C2C0A8AE-F5AA-40D3-9D7B-BAA11C32C9D2Q33813357-A6C0E3B7-E8EB-4300-A25B-428C31A2A308Q34568353-B5926E21-1489-483E-8761-F0B3F3D7B847Q34785177-1DFF1BDF-2FAC-4152-8B92-50C10319007EQ34788920-908F4E4E-DBAE-4762-BCEA-39BE154AF47BQ34991612-1629A1F2-7DDD-4038-A675-678B18D5A596Q36072517-15E75D3C-6B69-4665-A005-49A6E1DF52CDQ36547859-67517884-63A2-4D97-90B2-1CBCA998542FQ36576517-8B17CF01-9A2D-4FD4-82EB-0FCB5ACAE6D5Q36672445-A30AB1B6-D3EB-4BA0-904F-E2C23F128DFAQ36799410-7DBDC003-B4B7-4C7E-B65C-81A7C42E52A9Q36835374-CDDE165A-A084-482A-B214-F62AAD5E1A8FQ36955365-51C632B4-8E3F-4C15-B87D-86C38332131FQ37184422-3184E9FD-CF53-413E-A5E1-AA155D2DC8D4Q37350908-69DD1EE0-F5A0-476A-B90F-4F6C242998A8Q37462448-229B695B-FB32-4AEA-85C0-862923AE792CQ37677789-944E11B4-D069-4E1C-B1EB-7EB666E6E3C1Q37755049-995C78F2-B3AF-4686-8606-B28FC2B1EB65Q37775799-BED34794-1BFE-4B8A-9DC8-C3DC6429DDF0Q37867110-F656E870-01B4-4369-BC2B-EFE603BCCE56Q38218544-36A16E9B-6661-4CDA-906A-833B4765BEB3Q38292450-BFCB55C3-32AF-4035-A64E-9677D186E6F5Q38675211-07F77D00-510E-4FE1-9C8A-EA98E594D2DDQ40886514-C984B422-8EBB-4F4A-B9F6-825B059090C1Q50454272-5C07DA00-0AF9-44C2-A551-2371F2026D54
P2860
In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
In vitro, ex vivo, and in vivo ...... es: how biomarkers can assist?
@ast
In vitro, ex vivo, and in vivo ...... es: how biomarkers can assist?
@en
type
label
In vitro, ex vivo, and in vivo ...... es: how biomarkers can assist?
@ast
In vitro, ex vivo, and in vivo ...... es: how biomarkers can assist?
@en
prefLabel
In vitro, ex vivo, and in vivo ...... es: how biomarkers can assist?
@ast
In vitro, ex vivo, and in vivo ...... es: how biomarkers can assist?
@en
P2093
P356
P1476
In vitro, ex vivo, and in vivo ...... es: how biomarkers can assist?
@en
P2093
Henriksen K
Hoegh-Andersen P
Karsdal MA
Schaller S
Søndergaard BC
P304
P356
10.1089/ADT.2005.3.553
P577
2005-10-01T00:00:00Z